Example ImageÃÀ¸ß÷

EN
EN
  • ÓªÒµ×Éѯ

    Öйú£º

    Email: marketing@medicilon.com.cn

    ÓªÒµ×ÉѯרÏߣº400-780-8018

    £¨½öÏÞЧÀÍ×Éѯ£¬£¬£¬ÆäËûÊÂÒËÇ벦´ò´¨É³×ܲ¿µç»°£©

    ´¨É³×ܲ¿µç»°: +86 (21) 5859-1500

    ÍâÑó£º

    +1(781)535-1428(U.S.)

    0044 7790 816 954 (Europe)

    Email:marketing@medicilon.com

ÔÚÏßÁôÑÔ¡Á
µã»÷Çл»
Customer Center
¿Í»§ÖÐÐÄ

بϲÉúÎïÐû¹«¸æ¿¢ÖÁ¶à1.5ÒÚÃÀԪ˽ļÅäÊÛÈÚ×ÊØ­¡°ÃÀ¡±ÌìÐÂÒ©ÊÂ

2023-08-08
|
»á¼ûÁ¿£º

¸±±¾_¸±±¾_ÍøÕ¾ËõÂÔͼ__2023-08-08+15_07_05.jpeg

Ò½ÏßÒ©ÎÅ

1¡¢¿ËÈÕ£¬£¬£¬ÀÅîÚ¼¯ÍÅÐû²¼¡¸ÑÎËáÌæÂåÀûÉúƬ£¨Ñ¡ÔñÐÔ×é°·H3ÊÜÌå·´Ïò¼¤¶¯¼Á£©¡¹×îÐÂÊý¾Ý¡£¡£¡£ÖйúµÄ±¬·¢ÐÔ˯²¡»¼ÕßÔÚ½ÓÊÜÑÎËáÌæÂåÀûÉúƬÖÎÁƺ󣬣¬£¬ÆäÈÕ¼äÌ«¹ýÊÈ˯»ñµÃÏÔÖø¸ÄÉÆ£¬£¬£¬ÖðÈÕâ§µ¹±¬·¢´ÎÊýÏÔÖø½µµÍ£¬£¬£¬²¢ÇÒ¸ÃÒ©Çå¾²ÄÍÊÜÐÔÓÅÒ죬£¬£¬Î´·ºÆðÈκÎÑÏÖØ²»Á¼ÊÂÎñ¡£¡£¡£

2¡¢¿ËÈÕ£¬£¬£¬ºãÈðÒ½Ò©½ÒÏþ¿¹PD-1µ¥¿¹¡¸×¢ÉäÓÿ¨ÈðÀûÖéµ¥¿¹¡¹ÁªºÏ»¯ÁƱÈÕÕ»¯ÁÆ£¬£¬£¬Ð¸¨ÖúÖÎÁÆ¢óA/¢óBÆÚ·ÇСϸ°û·Î°©£¨NSCLC£©µÄIIÆÚЧ¹û¡£¡£¡£Ó뻯ÁƵ¥Ò©Ïà±È£¬£¬£¬ÁªºÏÁÆ·¨ÏÔÖøÌá¸ßNSCLC»¼ÕߵIJ¡ÀíÍêÈ«»º½âÂÊ£¨32.6% vs 8.9%£©£¬£¬£¬²¢ÇÒÇå¾²ÐÔÓÅÒì¡£¡£¡£

3¡¢¿ËÈÕ£¬£¬£¬ÉϺ£Ò½Ò©Í¨¸æ³Æ£¬£¬£¬ÆäÈ«×Ê×Ó¹«Ë¾É걨µÄ¡¸°ÐÏòCD19ºÍCD22µÄǶºÏ¿¹Ô­ÊÜÌå×ÔÌåTϸ°û×¢ÉäÒº£¨B019£©¡¹ÁÙ´²ÊÔÑéÉêÇë»ñµÃÊÜÀí£¬£¬£¬ÄâÓÃÓÚÖÎÁƸ´·¢»òÄÑÖÎÐÔBÁܰÍϸ°ûÖ×Áö¡£¡£¡£B019½ÓÄÉÒ»¸ö˫˳·´×ÓÔØÌå½á¹¹£¬£¬£¬¿ÉÒÔÔÚTϸ°ûÉϱí´ïÁ½¸ö×ÔÁ¦µÄǶºÏ¿¹Ô­ÊÜÌå¡£¡£¡£

ͶÈÚÒ©ÊÂ

1¡¢¿ËÈÕ£¬£¬£¬Ø¨Ï²ÉúÎï¿Æ¼¼¼¯ÍŹ«Ë¾Ðû²¼ÒÑÓë¶à¼Ò×ÅÃûÒ½ÁÆÐÐÒµ»ú¹¹Í¶×ÊÕßÇ©ÊðÁËÒ»Ïî˽ļÅäÊÛÈϹºÐ­Òé¡£¡£¡£±¾´ÎÉúÒâÓÉVivo CapitalÁìͶ£¬£¬£¬Adage Capital Partners LP£¬£¬£¬Exome Asset Management£¬£¬£¬Janus Henderson Investors£¬£¬£¬Logos Capital£¬£¬£¬OrbiMed£¬£¬£¬Pivotal Life Sciences£¬£¬£¬RA Capital Management ¼°TCGXµÈÏÖÓм°ÐÂÔö»ú¹¹Í¶×ÊÕß²ÎͶ¡£¡£¡£Í¨Ë׹ɵÄÅäÊÛ½«ÕÙļ1ÒÚÃÀÔª£»£»£»£» £»£»ÈôÈϹÉȨ֤±»ËùÓÐÐÐʹ£¬£¬£¬¹«Ë¾½«½øÒ»²½»ñµÃ5000ÍòÃÀÔªµÄÌØÊâÕÙļ×ʽ𡣡£¡£¸ÃÈϹÉȨ֤½«ÔÚ˽ļÅäÊÛÍê³ÉºóµÄ24¸öÔÂÄÚÓÉͶ×ÊÕßÑ¡ÔñÐÐʹ¡£¡£¡£

¿Æ¼¼Ò©ÑÐ

1¡¢8ÔÂ4ºÅ£¬£¬£¬Öйúҽѧ¿ÆÑ§Ôº/±±¾©Ð­ºÍÒ½Ôº/±±¾©Ð­ºÍҽѧԺÑо¿Ö°Ô±ÔÚ¹ú¼Ê×ÅÃûÆÚ¿¯¡¶Cell Death&Disease¡·ÉϽÒÏþÑо¿ÂÛÎÄ£¬£¬£¬¸ÃÑо¿·¢Ã÷½ÇöèÏ©»·Ñõ»¯Ã¸(SQLE)ÊÇÒÈÏÙ°©Éú³¤Àú³ÌÖе¨¹Ì´¼´úлµÄÖ÷Òªµ÷ÀíÒò×Ó¡£¡£¡£Ñо¿Ö°Ô±ÊӲ쵽SQLEÔÚÒÈÏÙ°©×éÖ¯ÖÐÏÔÖøÉϵ÷£¬£¬£¬Æä¸ß±í´ïÓ뻼Õß²»Á¼Ô¤ºóÏà¹Ø¡£¡£¡£±¾Ñо¿Õ¹ÏÖÁËSQLE×÷ΪһÖÖÐµİ©»ùÒò£¬£¬£¬Í¨¹ý»º½âÄÚÖÊÍøÓ¦¼¤ºÍ¼¤»îÖ¬·¤µ÷ÀíµÄSrc/PI3K/AktÐźÅͨ·À´Ôö½øÒÈÏÙ°©Éú³¤£¬£¬£¬Í»ÏÔÁËSQLE×÷ΪÒÈÏÙ°©ÖÎÁưеãµÄDZÁ¦[1]¡£¡£¡£

2¡¢8ÔÂ3ÈÕ£¬£¬£¬Ç廪´óѧҽѧԺÀÌοÎÌâ×é¡¢±±¾©ÉúÃü¿ÆÑ§Ñо¿Ëù/Ç廪´óѧÉúÎïҽѧ½»Ö¯Ñо¿ÔºÀîÎĻԿÎÌâ×éºÍÇ廪´óѧҽѧԺÍõ´óÁÁ¸±½ÌÊÚÏàÖú£¬£¬£¬ÔÚNature CommunicationsÔÓÖ¾ÔÚÏß½ÒÏþÑо¿ÂÛÎÄ£¬£¬£¬±¨µÀÁËHBV±àÂëµÄÒªº¦µ÷¿ØÂѰ×HBxÔõÑùͨ¹ýÐ®ÖÆºÍʹÓñí¹ÛÒò×ÓSpindlin1ÂѰ×À´¹¥¿ËÒìȾɫÖÊÕϰ­½ø¶øÔö½øHBV cccDNAת¼µÄ·Ö×Ó»úÀí[2]¡£¡£¡£

3¡¢8ÔÂ3ÈÕ£¬£¬£¬ÔÚÒ»ÏîеÄÑо¿ÖУ¬£¬£¬À´×ÔÐÂ¼ÓÆÂ¹úÁ¢´óѧҽѧԺ΢ÉúÎïѧÓëÃâÒßѧϵÖúÀí½ÌÊÚJohn Chen²©Ê¿ºÍµÛ¹úÀí¹¤Ñ§ÔºÑ¬È¾²¡Ïµ½ÌÊÚJos¨¦ R. Penad¨¦s²©Ê¿µÄÑо¿ÍŶӷ¢Ã÷ÁËϸ¾úÈö²¥ËüÃǵĻùÒòµÄÒ»ÖÖз½·¨£¬£¬£¬ÕâÖÖ·½·¨Ê¹Ï¸¾úµÄ½ø»¯ËÙÂÊÔ¶Ô¶Áè¼ÝÁËÈËÃÇÒÔǰµÄÃ÷È·¡£¡£¡£Õâһп´·¨¿ÉÄÜÓÐÖúÓÚ¿ÆÑ§¼ÒÃǸüºÃµØÃ÷È·Ö²¡Ï¸¾úÔõÑù½ø»¯²¢±äµÃ¶¾ÐÔÔ½À´Ô½Ç¿¡¢¶Ô¿¹ÉúËØÔ½À´Ô½ÄÍÒ©¡£¡£¡£Ïà¹ØÑо¿Ð§¹û½ÒÏþÔÚCellÆÚ¿¯ÉÏ[3]¡£¡£¡£

[1]Ruiyuan X,Jianlu S,Rexiati R, et al. SQLE promotes pancreatic cancer growth by attenuating ER stress and activating lipid rafts-regulated Src/PI3K/Akt signaling pathway[J]. Cell Death & Disease,2023,14(8).

[2]Wei L,Qiyan Y,Xiaonan S, et al. Molecular insights into Spindlin1-HBx interplay and its impact on HBV transcription from cccDNA minichromosome.[J]. Nature communications,2023,14(1).

[3]Melissa Su Juan Chee et al. Dual pathogenicity island transfer by piggybacking lateral transduction. Cell, 2023, doi:10.1016/j.cell.2023.07.001.

¹Ø×¢¡°ÃÀ¸ß÷Medicilon¡±¹«Öںţ¬£¬£¬¶©ÔÄÀ¸Ä¿»ñÈ¡ÌìÌìÒ½Ò©×ÊѶ-1.png

Ïà¹ØÐÂÎÅ
¡Á
ËÑË÷ÑéÖ¤
µã»÷Çл»
¡¾ÍøÕ¾µØÍ¼¡¿¡¾sitemap¡¿